» Articles » PMID: 33509939

The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention

Overview
Journal Cancer Res
Specialty Oncology
Date 2021 Jan 29
PMID 33509939
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas, and hematopoietic system. Here, we discuss CDCP1 as an important hub for oncogenic signaling and its key roles in malignant transformation and summarize approaches focused on exploiting it for cancer diagnosis and therapy. Elevated levels of CDCP1 are associated with progressive disease and markedly poorer survival. Predominantly located on the cell surface, CDCP1 lies at the nexus of key tumorigenic and metastatic signaling cascades, including the SRC/PKCδ, PI3K/AKT, WNT, and RAS/ERK axes, the oxidative pentose phosphate pathway, and fatty acid oxidation, making important functional contributions to cancer cell survival and growth, metastasis, and treatment resistance. These findings have stimulated the development of agents that target CDCP1 for detection and treatment of a range of cancers, and results from preclinical models suggest that these approaches could be efficacious and have manageable toxicity profiles.

Citing Articles

Three-protein signature is associated with baseline and persistently elevated or recurrent depressive symptoms in individuals with recent-onset diabetes.

Spagnuolo M, Gottmann P, Sommer J, Borgmann S, Strassburger K, Rathmann W BMJ Open Diabetes Res Care. 2025; 13(1).

PMID: 39965868 PMC: 11836832. DOI: 10.1136/bmjdrc-2024-004396.


Ligands of CD6: roles in the pathogenesis and treatment of cancer.

Gurrea-Rubio M, Lin F, Wicha M, Mao-Draayer Y, Fox D Front Immunol. 2025; 15:1528478.

PMID: 39840036 PMC: 11747410. DOI: 10.3389/fimmu.2024.1528478.


Causal relationships between the gut microbiota, inflammatory cytokines, and alcoholic liver disease: a Mendelian randomization analysis.

Li S, Zhou C, Liu T, Zhang L, Liu S, Zhao Q Front Endocrinol (Lausanne). 2024; 15:1442603.

PMID: 39497803 PMC: 11532067. DOI: 10.3389/fendo.2024.1442603.


Olink and gut microbial metabolomics reveal new biomarkers for the prediction and diagnosis of PMOP.

Wu R, Wu J, Jin H, Ma H, Huang H, Xu W J Bone Miner Metab. 2024; 42(5):503-515.

PMID: 39153113 DOI: 10.1007/s00774-024-01545-z.


Measuring Interactions Between Proteins and Small Molecules or Nucleic Acids.

Lackner A, Qiu Y, Armanus E, Macapagal A, Leonidas L, Xu H Curr Protoc. 2024; 4(7):e1105.

PMID: 39040024 PMC: 11335060. DOI: 10.1002/cpz1.1105.